Relay Therapeutics Inc RLAY.OQ RLAY.O is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2024
The Cambridge Massachusetts-based company is expected to report revenue of $6.08 million, according to the mean estimate from 10 analysts, based on LSEG data.
LSEG's mean analyst estimate for Relay Therapeutics Inc is for a loss of 56 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Relay Therapeutics Inc is $20.00, above its last closing price of $3.92.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -0.76 | -0.77 | -0.63 | Beat | 17.9 |
Jun. 30 2024 | -0.73 | -0.73 | -0.69 | Beat | 5.8 |
Mar. 31 2024 | -0.69 | -0.70 | -0.62 | Beat | 12 |
Dec. 31 2023 | -0.69 | -0.73 | -0.67 | Beat | 8 |
Sep. 30 2023 | -0.82 | -0.83 | -0.54 | Beat | 35 |
Jun. 30 2023 | -0.84 | -0.82 | -0.81 | Beat | 0.7 |
Mar. 31 2023 | -0.66 | -0.69 | -0.78 | Missed | -12.8 |
Dec. 31 2022 | -0.71 | -0.70 | -0.56 | Beat | 20.3 |
This summary was machine generated February 24 at 22:00 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。